VMI
PRVL

VHCP Management III’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

VHCP Management III’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4,408
Closed -$54K – 24
2019
Q3 		$54K Buy
+4,408
New +$50K 0.03% 17

Other funds holding PRVL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VHCP Management III's PRVL Position: Q4 2019 in Review

VHCP Management III sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q4 2019, closing a stake of 4,408 shares — an estimated $54K sold.

VHCP Management III first reported a position in PRVL in Q3 2019 and held it in 1 quarter. The position peaked at $54K in Q3 2019. 46 funds tracked by Wall St. Rank hold PRVL as of Q4 2019.

  • VHCP Management III reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • VHCP Management III sold 4,408 Prevail Therapeutics Inc. Common Stock shares in Q4 2019, an estimated $54K.
  • VHCP Management III first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • VHCP Management III's Prevail Therapeutics Inc. Common Stock position peaked at $54K in Q3 2019.
  • 46 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q4 2019.

Based on VHCP Management III's 13F filing for Q4 2019, filed 13 Feb 2020.